中国康复理论与实践
中國康複理論與實踐
중국강복이론여실천
CHINESE JOURNAL OF REHABILITATION THEORY & PRACTICE
2014年
3期
259-261
,共3页
邓元央%黄海能%韦桂源%黄华东%罗起胜%符黄德%李传玉
鄧元央%黃海能%韋桂源%黃華東%囉起勝%符黃德%李傳玉
산원앙%황해능%위계원%황화동%라기성%부황덕%리전옥
β-七叶皂苷钠%重型颅脑损伤%肿瘤坏死因子-α
β-七葉皂苷鈉%重型顱腦損傷%腫瘤壞死因子-α
β-칠협조감납%중형로뇌손상%종류배사인자-α
β-aescine sodium%severe traumatic brain injury%tumor necrosis factorα
目的:研究β-七叶皂苷钠对重型脑损伤患者血清肿瘤坏死因子-α(TNF-α)的影响及其临床意义。方法60例重型脑损伤患者分为治疗组和对照组各30例,对照组给予神经外科常规治疗,治疗组在常规治疗基础上给予β-七叶皂苷钠。分别于治疗前,治疗后第1、2、3、5、7天测定血清TNF-α,于治疗3个月后进行格拉斯哥结局量表(GOS)评分。结果治疗3 d后,治疗组血清TNF-α较对照组下降(P<0.05);治疗3个月后,治疗组GOS评分优于对照组(P<0.05)。结论β-七叶皂苷钠是治疗重型脑损伤的有效手段之一,血清TNF-α的动态变化能够预测治疗结局。
目的:研究β-七葉皂苷鈉對重型腦損傷患者血清腫瘤壞死因子-α(TNF-α)的影響及其臨床意義。方法60例重型腦損傷患者分為治療組和對照組各30例,對照組給予神經外科常規治療,治療組在常規治療基礎上給予β-七葉皂苷鈉。分彆于治療前,治療後第1、2、3、5、7天測定血清TNF-α,于治療3箇月後進行格拉斯哥結跼量錶(GOS)評分。結果治療3 d後,治療組血清TNF-α較對照組下降(P<0.05);治療3箇月後,治療組GOS評分優于對照組(P<0.05)。結論β-七葉皂苷鈉是治療重型腦損傷的有效手段之一,血清TNF-α的動態變化能夠預測治療結跼。
목적:연구β-칠협조감납대중형뇌손상환자혈청종류배사인자-α(TNF-α)적영향급기림상의의。방법60례중형뇌손상환자분위치료조화대조조각30례,대조조급여신경외과상규치료,치료조재상규치료기출상급여β-칠협조감납。분별우치료전,치료후제1、2、3、5、7천측정혈청TNF-α,우치료3개월후진행격랍사가결국량표(GOS)평분。결과치료3 d후,치료조혈청TNF-α교대조조하강(P<0.05);치료3개월후,치료조GOS평분우우대조조(P<0.05)。결론β-칠협조감납시치료중형뇌손상적유효수단지일,혈청TNF-α적동태변화능구예측치료결국。
Objective To study the effect ofβ-aescine sodium on tumor necrosis factorα(TNF-α) in patient with severe traumatic brain injury and the clinical significance. Methods 60 patients with severe traumatic brain injury were divided equally into control group (n=30) and treatment group (n=30), who accepted routine therapy and furtherβ-aescine sodium respectively. The serum TNF-αwas determined before and 1 d, 2 d, 3 d, 5 d and 7 d after treatment. The patients were assessed with Glasgow Outcome Scale (GOS) 3 months after treat-ment. Results There was significant difference of serum TNF-αbetween treatment group and control group since 3 d after treatment (P<0.05). The score of GOS was better in the treatment group than in the control group 3 months after treatment (P<0.05). Conclusionβ-aes-cine sodium is effective on severe traumatic brain injury. Level of TNF-αmay be related with the outcome of patients with severe traumatic brain injury.